Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Soon

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Dec 24, 2020 12:19pm

143 Views

Post# 32178086

RE:RE:RE:RE:RE:Soon

bringon10bagger wrote: Time for a little back scratching....Khouri is in the know?.

MrMugsy wrote:

Pandora wrote:
I see Knight Therapeutics has just issued a shelf prospectus for $360 million in share issue.
No idea what their intention is but they do mention the word acquisition. Personally I would not like to see Knight taking a bigger interest in Antibe. Hopefully Goodman is looking elsewhere.

I'm sure he's looking elsewhere too ... but ... he really should be trying to get the Latin American licenses to OTENA. Maybe even Australia and New Zealand while he's at it.

I don't think he's interested in any other regions. IMO.